Home › Therapeutic areas › Oncology › Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (25 companies)
Companies with an active program in Non-Small Cell Lung Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | Oncology | 1 | Phase 2 | 5 |
| ACTU | Actuate Therapeutics | Oncology | 1 | Phase 2 | 8 |
| AKTS | Aktis Oncology | Oncology | 2 | Phase 1 | 9 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | 15 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 3 | Phase 1 | 8 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 1 | 10 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | 10 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | 21 |
| FHTX | Foghorn Therapeutics | Oncology | 1 | Phase 1 | 1 |
| IMTX | Immatics | Oncology | 2 | Phase 2 | 8 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | 5 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | NDA Submitted | 16 |
| IMNM | Immunome | Oncology | 1 | NDA Submitted | 9 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | 9 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | 7 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 2 | 11 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | 6 |
| NVCT | Nuvectis Pharma | Oncology | 1 | Phase 1 | 3 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | 7 |
| SMMT | Summit Therapeutics | Oncology | 1 | Phase 3 | 3 |
| TNGX | Tango Therapeutics | Oncology | 2 | Phase 1 | 6 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | 10 |
| XNCR | Xencor | HematologyImmunology+4 Rare | 1 | Approved | 30 |
| ZYME | Zymeworks | OncologyRespiratory | 2 | Approved | 11 |
No companies match.